

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer ID4006

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
Merck Sharpe and Dohme	All Wales Therapeutics and Toxicology
(pembrolizumab)	Centre
- · · · ·	 Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Asthma and Lung UK Disply Lightly Agency for Equality	Wales
Black Health Agency for EqualityCancer Black Care	British National Formulary Care Quality Commission
Cancer Equality	Care Quality CommissionDepartment of Health, Social Services
Helen Rollason Cancer Charity	and Public Safety for Northern Ireland
 Independent Cancer Patients Voice 	Healthcare Improvement Scotland
Macmillan Cancer Support	Medicines and Healthcare products
Maggie's Centres	Regulatory Agency
Marie Curie	 National Association of Primary Care
Oncogene-Driven Lung Cancer	 National Pharmacy Association
Patient Alliance UK	NHS Confederation
Roy Castle Lung Cancer Foundation	Scottish Medicines Consortium
Ruth Strauss Foundation	Welsh Government
South Asian Health Foundation	Welsh Health Specialised Services
Specialised Healthcare Alliance Tanana Canana Canana	Committee
Tenovus Cancer Care His Lyng Cancer Capition	Comparator companies
UK Lung Cancer Coalition	Bristol Myers Squibb (paclitaxel)
Healthcare professional groups	Pfizer UK (carboplatin, cisplatin,
Association of Anaesthetists	paclitaxel)
Association of Cancer Physicians	Sandoz (cisplatin)
Association of Respiratory Nurse	Seacross pharmaceuticals (paclitaxel)
Specialists	 Teva UK (paclitaxel)
Association of Surgeons of Great	
Britain and Ireland	Other relevant company
British Geriatrics Society	AstraZeneca (olaparib)
British Institute of Radiology British Organism Plantage	Relevant research groups
British Oncology Pharmacy Association	Cochrane Lung Cancer Group
Association	Cochrane UK
British Psychosocial Oncology Society	- Coomane on

Provisional stakeholder list for evaluation of pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer ID4006

Issue date: November 2023



Consultees	Commentators (no right to submit or appeal)
 British Society of Interventional Radiology British Thoracic Oncology Group British Thoracic Society British Transplantation Society Cancer Research UK Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
Department of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for evaluation of pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer ID4006

Issue date: November 2023



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.